Table 4 Microbiological cure or eradication in primary bacteremia patients receiving C/T
From: Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR)
Author, year | Study design | Pathogen type | Antibiotic resistance | Outcome definition | Time point | % (n/N) Reporting cure or eradication |
|---|---|---|---|---|---|---|
Retrospective cohort studies | ||||||
 Elabor et al., 2018 [15] | Retrospective cohort | Pseudomonas: 100% (not further specified) | MDR infection: 100% | Defined as the presence of a repeat negative culture after initiation of treatment | – | 100% (4/4) |
 Gallagher et al., 2018 [17] | Retrospective cohort | Pseudomonas: 100% (not further specified) | MDR infection: 100% | Defined as a negative culture at the end of therapy | – | 100% (6/6) |
 King et al., 2018 [11] | Retrospective cohort | Pseudomonas: 100% (not further specified) | MDR infection: 100% | Microbiological success required a negative culture at the end of therapy | – | 100% (7/7) |